Imsamotide

依沙莫肽

Report date: 2026/04/28 20:00:22

Base Information

Drug NameImsamotide
Drug Alias NameIDOlongindoleamine 2,3-dioxygenase 1 (IDO1) peptideIDO-derived peptide vaccineImsapepimutIO-102
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsOropharyngeal Squamous Cell Carcinoma (OPSCC)Oral Squamous Cell CarcinomaCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumNetherlandsDenmark +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHerlev HospitalMerck Sharp & Dohme CorpIo Biotech Aps
China Registration ClassN/A

Develop Information

Active CompaniesIo Biotech ApsMerck Sharp & Dohme LLC
Inactive CompaniesCliniques Universitaires Saint-Luc A.S.B.L.Herlev Hospital
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsOropharyngeal Squamous Cell Carcinoma (OPSCC)Oral Squamous Cell CarcinomaCarcinoma, Squamous Cell +[4] 

Other Information

ATC CodeN/A
Related LinksN/A